永顺生物(839729) - 2024 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter of 2024 was CNY 66,495,478.87, representing a decrease of 18.00% year-on-year[9] - Net profit attributable to shareholders for the first quarter of 2024 was CNY 8,374,511.51, down 59.92% from the same period last year[9] - Total operating revenue for Q1 2024 was CNY 66,495,478.87, a decrease of 17.9% compared to CNY 81,091,529.35 in Q1 2023[34] - Net profit for Q1 2024 was CNY 8,374,511.51, a decline of 60.0% from CNY 20,894,809.49 in Q1 2023[35] - Total profit for Q1 2024 was CNY 9,420,501.30, a decrease of 60.5% from CNY 23,804,973.70 in Q1 2023[35] - Earnings per share for Q1 2024 was CNY 0.03, compared to CNY 0.08 in Q1 2023[36] - Operating profit for Q1 2024 was CNY 9,360,944.99, down 50.5% from CNY 18,870,406.93 in Q1 2023[35] Cash Flow - The net cash flow from operating activities increased by 214.57% to CNY 16,510,126.57 compared to the previous year[9] - The cash inflow from operating activities for Q1 2024 was CNY 67,850,571.06, an increase of 9.7% compared to CNY 61,928,602.02 in Q1 2023[39] - The net cash flow from operating activities for Q1 2024 was CNY 16,510,126.57, a significant recovery from a negative CNY 14,410,166.78 in Q1 2023[39] - The cash inflow from investment activities in Q1 2024 was CNY 46,599,181.42, while the cash outflow was CNY 31,004,727.00, resulting in a net cash flow of CNY 15,594,454.42[40] - The cash inflow from financing activities for Q1 2024 was CNY 12,785,666.05, compared to CNY 35,100,000.00 in Q1 2023, indicating a decrease of 63.5%[40] - The net increase in cash and cash equivalents for Q1 2024 was CNY 44,629,965.73, contrasting with a decrease of CNY 36,683,350.52 in Q1 2023[40] - The total cash outflow for operating activities in Q1 2024 was CNY 51,340,444.49, down from CNY 76,338,768.80 in Q1 2023, reflecting a reduction of 32.8%[39] Assets and Liabilities - Total assets as of March 31, 2024, reached CNY 801,866,008.23, an increase of 1.78% compared to the previous year[9] - The company's asset-liability ratio remained stable at 15.58% for both the parent and consolidated entities[9] - Current liabilities rose to CNY 114,482,878.12, up from CNY 108,233,580.73, indicating an increase of about 3.1%[30] - Short-term borrowings increased significantly to CNY 27,388,015.75 from CNY 19,401,038.96, representing a rise of approximately 41.1%[30] - The total liabilities increased to CNY 124,941,331.40 from CNY 119,309,799.39, reflecting a growth of approximately 4.4%[30] - The company's total equity reached CNY 676,924,676.83, up from CNY 668,550,165.32, marking an increase of about 0.6%[30] - The company's total non-current assets amounted to CNY 219,383,096.16, down from CNY 226,312,983.97, indicating a decrease of about 3.1%[32] Shareholder Information - The total number of shares held by the top ten shareholders is 209,022,215, accounting for 76.47% of the total shares[18] - The largest shareholder, Guangdong Modern Agriculture Group Co., Ltd., holds 39.0638% of the shares, while the second-largest shareholder, Guangdong Agricultural Science Assets Management Co., Ltd., holds 19.7081%[19] - The company has no pledged or judicially frozen shares among its top ten shareholders[20] Other Financial Metrics - The company reported a significant decrease in investment income by 91.34% to CNY 42,234.34 due to changes in investment structure[11] - The gross profit margin declined due to a shift in product sales structure, with a notable increase in the sales proportion of lower-margin products[11] - Research and development expenses for Q1 2024 were CNY 5,350,715.65, a decrease of 19.5% from CNY 6,647,428.05 in Q1 2023[34] - Other income for Q1 2024 was CNY 1,248,740.12, an increase from CNY 1,133,581.43 in Q1 2023[34] - Investment income for Q1 2024 was CNY 1,608,775.65, up from CNY 1,050,083.33 in Q1 2023[34] - The company reported a credit impairment loss of CNY 413,757.44 in Q1 2024, compared to a gain of CNY 894,878.38 in Q1 2023[35]